Overview

Nordic Pancreatic Cancer Trial (NorPACT) - 1

Status:
Active, not recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This study evaluate the additional effect of adding chemotherapy prior to resection of a pancreatic head malignancy. The patients will be randomized into two groups; surgery first (control group) and neoadjuvant chemotherapy (intervention). Primary endpoint is overall survival after resection
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Haukeland University Hospital
Helse Stavanger HF
St. Olavs Hospital
University Hospital of North Norway
Treatments:
Capecitabine
Fluorouracil
Gemcitabine
Irinotecan
Oxaliplatin